Keros Therapeutics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jasbir S. Seehra
- Full Time Employees
- 163
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 99 Hayden Avenue Lexington MA United States of America 02421
- IPO Date
- Apr 8, 2020
- CIK
- 0001664710
- Website
- kerostx.com
- Similar Companies
- Business
- Keros Therapeutics, Inc. is a biopharmaceutical enterprise, operating in the clinical development stage, dedicated to the discovery, evolution, and commercialization of innovative therapeutic agents. The company primarily targets disorders associated with dysregulated signaling of the transforming growth factor-beta (TGF-ß) protein family, which are integral to the regulation of blood, bone, skeletal muscle, and cardiac tissue health. Based in Lexington, Massachusetts, this firm aims to address significant unmet medical needs across various patient populations. Among its leading investigational medicines, elritercept, previously known as KER-050, is undergoing development for the management of cytopenias, encompassing both anemia and thrombocytopenia, in individuals afflicted with myelodysplastic syndromes and myelofibrosis, having progressed to Phase 3 clinical trials. Another key candidate, cibotercept, or KER-012, is being advanced for the treatment of pulmonary arterial hypertension and various cardiovascular conditions; its Phase 2 TROPOS study saw certain higher dose regimens paused in late 2024 due to observed adverse events, though dosing continues in a lower concentration arm with topline data anticipated in the second quarter of 2025. Additionally, KER-065 is in development for neuromuscular disorders, with an initial emphasis on Duchenne muscular dystrophy, having demonstrated positive Phase 1 outcomes and receiving Orphan Drug designation, and is slated for advancement into Phase 2 trials. The company has recently undertaken strategic financial actions, including the finalization of a substantial cash tender offer to repurchase shares as part of a larger capital return initiative in November 2025, alongside reporting strong cash reserves. Keros Therapeutics also holds a global license agreement with Takeda Pharmaceuticals for the further development and commercialization of elritercept in most regions worldwide.
Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference
Should You Buy KROS After Q1 Miss and Takeda Deal Reset?
KROS Turns to Next Wave of TGF-Beta Muscle Therapies
KROS Stock Guide to Rinvatercept in DMD and ALS for 2026
Keros Q1 Loss Wider Than Expected, Revenues Plunge Year Over Year
Keros Therapeutics, Inc. (KROS) Reports Q1 Loss, Misses Revenue Estimates
Keros Therapeutics Reports Recent First Quarter 2026 Financial Results
KROS 2026 Watchlist: 3 Catalysts That Could Reset Sentiment
KROS Stock: Does the Takeda Deal Lower Dilution Risk in 2026?
KROS Rinvatercept: What to Know Before DMD Phase II Starts
JPMorgan Chase & Co. Raises Position in Keros Therapeutics, Inc. $KROS
Why Is Keros Therapeutics (KROS) Up 2.5% Since Last Earnings Report?
KROS Stock: What to Know About Rinvatercept in DMD
KROS: Is the Discount Book Value a Value Trap?
KROS Pipeline Catalysts: DMD Phase II and ALS Plans for 2026
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Average Recommendation of “Hold” from Analysts
Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference
Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS
Can Keros Therapeutics Rinvatercept Stand Out in the DMD Market?
Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates